We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK Gets EU Approval for Expanded Use of Nucala in COPD
Read MoreHide Full Article
Key Takeaways
GSK's Nucala gained EU nod as an add-on maintenance treatment for certain COPD patients.
Phase III MATINEE data showed Nucala reduced moderate/severe COPD exacerbations versus placebo.
GSK's Nucala is the first and only biologic in the EU for COPD patients with an eosinophilic phenotype.
GSK plc (GSK - Free Report) announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for treating certain patients with chronic obstructive pulmonary disease (COPD), marking a new indication for the drug.
Nucala is now approved as an add-on maintenance treatment for uncontrolled COPD in adults who have a raised blood eosinophil count on a combination of an inhaled corticosteroid, a long-acting beta2-agonist and a long-acting muscarinic antagonist in the European Union.
The EU approval was expected as the Committee for Medicinal Products for Human Use of the European Medicines Agency rendered a positive opinion recommending the approval of Nucala as an add-on maintenance treatment for COPD in December 2025.
Nucala is the first and only monthly biologic in the EU to be studied in a broad group of COPD patients with an eosinophilic phenotype.
The FDA approved Nucala for the treatment of COPD in May last year, marking the fifth approved indication for the drug in the United States.
GSK’s Price Performance
Over the past six months, GSK’s shares have surged 57.5% compared with the industry’s rally of 43.5%.
Image Source: Zacks Investment Research
More on the EU Nod for GSK’s Nucala in COPD
The approval for Nucala in the EU was based on positive data from the phase III MATINEE study. Data from the same showed that treatment with Nucala led to a clinically meaningful and statistically significant reduction in the annualized rate of moderate/severe exacerbations versus placebo plus standard of care in a broad group of COPD patients.
Data from the MATINEE study also demonstrated treatment with Nucala led to a reduction in exacerbations, leading to emergency department visits and/or hospitalizations versus placebo.
Exacerbations are acute episodes of worsening COPD symptoms that can lead to hospitalization and irreversible lung damage. Preventing exacerbations is a key goal for managing COPD.
COPD affects more than 390 million people globally, including about 40 million in Europe. The disease ranks as one of the leading causes of hospitalization in many countries globally.
Nucala is a monoclonal antibody with a novel mechanism of action that targets IL-5, a key messenger protein (cytokine) in type 2 inflammation.
Besides COPD, Nucala is also approved in Europe and the United States for four other IL-5-mediated conditions. These are severe asthma, eosinophilic granulomatosis with polyangiitis, chronic rhinosinusitis with nasal polyps and hyper-eosinophilic syndrome.
Nucala generated sales worth £2.01 billion in 2025, increasing 15% year over year at constant exchange rate. The drug remains one of the key top-line drivers for GSK.
Over the past 60 days, estimates for Alkermes’ 2026 earnings per share (EPS) have increased from $1.54 to $1.91. Shares of ALKS have gained 26.1% over the past six months.
Alkermes’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 4.58%.
Over the past 60 days, Castle Biosciences’ loss per share estimates for 2026 have decreased from $1.06 to 96 cents. Shares of CSTL have surged 64.9% over the past six months.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 66.11%.
Over the past 60 days, Immunocore’s loss per share estimates for 2026 have decreased from 97 cents to 90 cents. Shares of IMCR have lost 3.1% over the past six months.
Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 53.96%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GSK Gets EU Approval for Expanded Use of Nucala in COPD
Key Takeaways
GSK plc (GSK - Free Report) announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for treating certain patients with chronic obstructive pulmonary disease (COPD), marking a new indication for the drug.
Nucala is now approved as an add-on maintenance treatment for uncontrolled COPD in adults who have a raised blood eosinophil count on a combination of an inhaled corticosteroid, a long-acting beta2-agonist and a long-acting muscarinic antagonist in the European Union.
The EU approval was expected as the Committee for Medicinal Products for Human Use of the European Medicines Agency rendered a positive opinion recommending the approval of Nucala as an add-on maintenance treatment for COPD in December 2025.
Nucala is the first and only monthly biologic in the EU to be studied in a broad group of COPD patients with an eosinophilic phenotype.
The FDA approved Nucala for the treatment of COPD in May last year, marking the fifth approved indication for the drug in the United States.
GSK’s Price Performance
Over the past six months, GSK’s shares have surged 57.5% compared with the industry’s rally of 43.5%.
Image Source: Zacks Investment Research
More on the EU Nod for GSK’s Nucala in COPD
The approval for Nucala in the EU was based on positive data from the phase III MATINEE study. Data from the same showed that treatment with Nucala led to a clinically meaningful and statistically significant reduction in the annualized rate of moderate/severe exacerbations versus placebo plus standard of care in a broad group of COPD patients.
Data from the MATINEE study also demonstrated treatment with Nucala led to a reduction in exacerbations, leading to emergency department visits and/or hospitalizations versus placebo.
Exacerbations are acute episodes of worsening COPD symptoms that can lead to hospitalization and irreversible lung damage. Preventing exacerbations is a key goal for managing COPD.
COPD affects more than 390 million people globally, including about 40 million in Europe. The disease ranks as one of the leading causes of hospitalization in many countries globally.
Nucala is a monoclonal antibody with a novel mechanism of action that targets IL-5, a key messenger protein (cytokine) in type 2 inflammation.
Besides COPD, Nucala is also approved in Europe and the United States for four other IL-5-mediated conditions. These are severe asthma, eosinophilic granulomatosis with polyangiitis, chronic rhinosinusitis with nasal polyps and hyper-eosinophilic syndrome.
Nucala generated sales worth £2.01 billion in 2025, increasing 15% year over year at constant exchange rate. The drug remains one of the key top-line drivers for GSK.
GSK’s Zacks Rank & Stocks to Consider
GSK currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Alkermes (ALKS - Free Report) , Castle Biosciences (CSTL - Free Report) and Immunocore (IMCR - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Alkermes’ 2026 earnings per share (EPS) have increased from $1.54 to $1.91. Shares of ALKS have gained 26.1% over the past six months.
Alkermes’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 4.58%.
Over the past 60 days, Castle Biosciences’ loss per share estimates for 2026 have decreased from $1.06 to 96 cents. Shares of CSTL have surged 64.9% over the past six months.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 66.11%.
Over the past 60 days, Immunocore’s loss per share estimates for 2026 have decreased from 97 cents to 90 cents. Shares of IMCR have lost 3.1% over the past six months.
Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 53.96%.